Photo Credit: Public domain by Open Grid Scheduler / Grid Engine via Flickr
Teva Pharmaceutical Industries

The U.S. Food and Drug Administration (FDA) granted its approval this week for TEVA Pharmaceutical’s new Leukemia treatment, TRISENOX® (arsenic trioxidec), according to a statement on the company’s website.

A medication administered by injection, TRISENOX® has been approved for use in combination with tretinoin for treatment of recently-diagnosed low-risk adults with acute promyelocytic leukemia (APL).


The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide.

Three months ago Teva announced the medication was to be granted priority by the FDA, with a decision expected in the first quarter of 2018.

“Today’s approval to expand the indication of TRISENOX® is a testament to Teva’s commitment to providing solutions to advance cancer care,” said Teva Oncology senior VP and general manager Paul Rittman.

“This label expansion represents an important benefit, as TRISENOX® is now an FDA-approved first line treatment option for patients with acute promyelocytic leukemia.”

The new indication reinforces the current practice guidelines by the National Comprehensive Cancer Network® (NCCN).

Share this article on WhatsApp:

Previous articleNamaste
Next articlePolice Foil Terror Attack Near Ma’ale Adumim
Hana Levi Julian is a Middle East news analyst with a degree in Mass Communication and Journalism from Southern Connecticut State University. A past columnist with The Jewish Press and senior editor at Arutz 7, Ms. Julian has written for, and other media outlets, in addition to her years working in broadcast journalism.